New injection aims to tame chronic hepatitis b

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants, aged 18-65 years old (inclusive) * Body Mass Index between 19 to 35 kg/m2 (inclusive) * Body weight \> or = 45 kg. * Documented HBV infection for ≥6 months prior to randomization. * For Parts A and B, on stable approved NA monotherapy for at least 6 months prior to randomization. * For Part C and D only, not on any NA monotherapy for at least 6 months prior to randomization. * Screening electrocardiogram (ECG) without clinically significant abnormalities * Females of childbearing potential must not be breastfeeding, must have a negative serum pregnancy test at Screening, and a negative urine/serum pregnancy test before dosing (unless permanently sterile or \>2 years postmenopausal). * Males and females of childbearing potential must agree to use protocol specified reliable contraception throughout the study. * Screening HBV DNA, HBsAg and ALT must meet prespecified requirements. Exclusion Criteria: * Significant medical conditions other than chronic HBV (e.g. recent heart issues, unstable cardiac disease, uncontrolled diabetes, bleeding disorders, prior organ transplant). * Other clinically significant liver diseases (e.g. hepatitis from other causes, autoimmune or alcoholic liver disease, prior liver failure). * History of suspected or confirmed cirrhosis (based on FibroScan® or biopsy). * Current, past, or suspected liver cancer, or elevated alpha-fetoprotein (AFP) ≥ 20 ng/mL. * HBV-related extrahepatic diseases (e.g. kidney or vascular conditions). * Severe infection (other than chronic HBV infection) within 1 month before randomization requiring intravenous treatment. * Active infections: human immunodeficiency virus (HIV), hepatitis C virus (HCV), hepatitis D virus (HDV) or syphilis (exceptions if RNA negative). * Abnormal lab results (e.g. low albumin, reduced kidney function, abnormal INR, low platelets, high bilirubin, abnormal blood counts, significant proteinuria). * History or signs of vasculitis or related autoimmune diseases. * Malignancy within 5 years (except non-melanoma skin cancer). * Allergy to study drug components. * Recent major surgery/trauma (within 3 months) or planned surgery during study. * Alcohol or substance abuse affecting compliance. * Pregnancy, breastfeeding, or unwillingness to follow reproductive restrictions. * Participation in another clinical trial or recent investigational product use. * Prior treatment with any antisense oligonucleotide or small interfering RNA therapies. * Recent or ongoing use of immunosuppressive/biologic therapies, certain vaccines, bulevirtide, or unapproved herbal remedies. * Need for long-term anticoagulants/antiplatelet drugs (unless safely stopped). * Any other condition making the participant unsuitable (per investigator).